Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer

NCT01142401 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01142401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01142401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 26, 2010
Completion date
January 8, 2021
Enrollment
118 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast carcinoma, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7